Company Milestones

Home > About Hanmi > History > Company Milestones

2010 December Hanmi transfers entecavir synthetic methods to Whail
December

Hanmi showcases RFID system in 'RFID/USN KOREA 2010'
December

Beijing Hanmi wins Korea-China Corporate Management Grand Prize
November

UK MHRA recommends approval of Pidogul
October

Hanmi submits IND application for Irbesartan-Atorvastatin combo
  September Hanmi receives IR52 Jang Young-Shil Award from KOITA
  August

Hanmi initiates the clinical trials of Amosartan in Europe
  August

Hanmi ranks 1st in R&D investment among Korean pharmaceutical companies

  July

Amosartan, The 1st approval as the initial therapy among CCB+ARB hypertension Combo Drugs
  May

Phase 1 underway for Atorvastatin plus Aspirin fixed dose combination drug
  April

LAPSCOVERY Platform Technology obtains US Patents
  April

Hanmi submits IMPD in Europe for phase I clinical trials of LAPS-Exendin
  March

Hanmi wins the best drug research award of KDRA
  February

Hanmi's Amosartan ranked the highest for detailing drugs
  February IND Application for long-acting Human Growth Hormone Approved
  January

KFDA Approves IND Application of Once Monthly Exendin4 analog